Terns Pharmaceuticals Names Andrew Gengos As New Chief Financial Officer

Terns Pharmaceuticals Inc. has selected Andrew Gengos to take on the role of chief financial officer, effective immediately. The clinical-stage biopharmaceutical firm focuses on small-molecule therapy development for oncology and obesity. Gengos arrives at the role after 25 years dedicated to life sciences, biotech finance, and strategy management. As CFO of Athira Pharma, he gained his latest experience before holding roles with Cyteir Therapeutics, ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals. 

Amy Burroughs, chief executive officer of Terns, said in a statement, “We are delighted to have Andrew join the Terns’ team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew’s contributions as we continue advancing our mission to transform patients’ lives by developing new medicines that have a valuable, enduring impact on human health.”

At Cyteir, he played a key role in taking the company public, and at Amgen, he spent eight years as VP of strategy and corporate development. Earlier in his career, Gengos worked at Morgan Stanley and McKinsey & Co., progressing to senior engagement manager. He holds an M.B.A. from the UCLA Anderson School of Management and a B.S. in Chemical Engineering from MIT. With his extensive financial and strategic leadership experience, Gengos is expected to support Terns Pharmaceuticals in advancing its portfolio and corporate growth.

Mr Andrew Gengos commented, “I am pleased to join Terns as we advance our lead oncology and obesity programs towards compelling clinical readouts later this year. I look forward to working with the talented Terns leadership team to build on the Company’s strong financial foundation and drive continued success in bringing new treatment options to patients battling serious diseases, including oncology and obesity.”